Home > Press > Harris & Harris Group Reports Financial Statements as of June 30, 2011
Abstract:
Harris & Harris Group, Inc., (NASDAQ:TINY) reported today that, as of June 30, 2011, its net asset value and net asset value per share (NAV) were $168,426,152 and $5.43, respectively.
As of June 30, 2011, we owned an aggregate of 2,304,149 shares of Solazyme. This position was valued at $44,354,868 as of June 30, 2011, which is included in our total assets of $173,384,222. The key inputs to our valuation of Solazyme were the share price as of the close of trading on June 30, 2011, which was $22.97, less a liquidity discount owing to the lock-up restrictions placed on the shares through an agreement with the underwriters of the IPO. As of August 5, 2011, Solazyme's closing price was $17.61 per share.
####
About Harris & Harris Group
Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems.
For more information, please click here
Copyright © Harris & Harris Group
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||